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Introduction
Most of the drugs that are used at present for cancer treatment are cytotoxic (cell-killing), affecting in one way or the other with the functioning of the DNA in cells. However, the biggest challenge in the development of new anticancer drugs is to find chemotherapeutic agents not only with high efficacy but also with low toxicity. It has been observed that though cisplatin has been used most successfully in the treatment of various types of cancers, it has been associated with side effects in addition to inherited or acquired resistance [1, 2] . Hence, chemists all over the world have been forced to look for an alternative approach in finding human friendly metal complexes to enhance the pharmacological properties. From among the various metal complexes studied so far, copper ion based complexes have been proved to be a promising alternative to platinum drugs [3] . Copper-based antineoplastic agents have shown remarkable results not only to test the altered metabolism of cancer cells but also to differentiate between cancer and normal cells [4] . In this connection, several copper-based synthetic nucleases have been reported [5] [6] [7] and a few of them have been found to cleave DNA hydrolytically [8, 9] . During the last several years, there has been a consistent and continuous effort in finding out the mode and extent of binding of metal complexes to DNA and protein and also to obtain vital information on understanding the cleavage properties of metal complexes for their biological applications.
Numerous inorganic chemists have chosen copper for its bio-essential activity and oxidative nature to establish its complexes for medical applications [10] [11] [12] [13] . In this area, copper complexes containing heterocyclic bases as ligands have been extensively explored in view of their strong interactions with DNA and of their cytotoxic activity [14] [15] [16] . In addition to this, copper complexes with their biologically accessible redox potentials have shown high nucleobase affinity with DNA [17] [18] [19] [20] [21] besides exhibiting an essential alternative to platinum drugs [22] [23] [24] [25] [26] [27] [28] . From the point of ligand used to prepare useful metal complexes, the combination of nitrogen containing heterocyclic ring and azomethine moiety might prove to be useful due to their potential biological and catalytic activities. Further, quinolines as well as their derivatives are also a class of ligands exhibiting a wide range of biological applications. In fact, some quinoline based Schiff base ligands and their Cu(II) complexes have been reported to show interesting pharmacological properties [29] [30] [31] [32] [33] [34] . Our perusal on the literature has indicated that no attention has been paid to explore the biological properties of 4-(diethylamino)-3-quinolin-3-ylimino-methyl-2-phenol and its Cu(II) complexes. Hence, we carried out the reaction of 4-(diethylamino)-3-quinolin-3-ylimino-methyl-2-phenol with [CuCl2(PPh3)2] and report the biological studies done on the ligand and that of the new complex.
Results and discussion

Synthesis
The synthetic route to the ligand and its Cu(II) complex are shown in Scheme 1 and they have been characterized by various spectroscopic techniques as discussed below. The ligand and complex are air stable and soluble in chloroform, dichloromethane, methanol, ethanol, dimethylformamide and dimethylsulfoxide. Scheme 1. Synthetic route of the ligand and its Cu(II) complex.
Spectroscopy
In the electronic spectra of ligand, three bands were observed in the region 282-402 nm, which are assigned to intra ligand transitions. Spectra of the complex exhibited two bands, the band observed at 254 nm was assigned to intra ligand transition and the band at 383 nm corresponds to ligand to metal charge transfer transition [35] [36] [37] . The IR spectrum, a band observed at 1628 cm -1 due to the C=N stretching of the ligand has been found shifted to 1606 cm -1 in the spectra of the complex, indicating coordination of the azomethine nitrogen atom to the Cu(II) ion. The band at 3432 cm -1 due to the -OH group in the free ligand disappeared completely in the spectra of the complex due to coordination of phenolic oxygen after deprotonation [38, 39] . The 1 H-NMR spectra of the ligand ( Figure S1 ), showed a sharp singlet at δ 8.93 ppm corresponding to the presence of a hydroxy group in the free ligand. A doublet at δ 8.42-8.43 ppm corresponds to the presence of the CH=N azomethine proton [40] . While a quartet observed around at δ 2.49-2.53 ppm corresponds to the CH2N group of protons in the ligand, a triplet observed at δ 1.11-1.14 ppm has been assigned to the terminal methylene group of protons [39] . The aromatic protons resonances of the ligand were observed in the range at δ 6.11-7.99 ppm. [43, 44] . The +2 oxidation state of the copper ion in the complex was confirmed by X-band EPR measured at room temperature. The copper complex showed well resolved isotropic resonance typical of square planar Cu(II) system ( Figure S3 ). From the g value of 2.01, it is proposed that the unpaired electron of Cu(II) ion is present in the dx2−y2orbital [45] .
X-ray crystallography
The complex crystallized in the triclinic space group P-1 with half a molecule in the asymmetric unit (Z'=0.5). Two ligands coordinated to the copper ion in a monobasic bidentate fashion through the imine nitrogen (N1) and phenolic oxygen (O1) forming a six-member chelate rings.
The Cu ( Crystal data and refinement details for the complex are presented in (Table   1 ). Important bond Length (Å) and bond angle (°) of the complex given in Table S1 (supporting information). 
DNA binding studies
In order for any compound to be tested for treating multiple pathologies including cancer, it is necessary to investigate the binding of such compound with DNA [46, 47] . One of the easiest ways is to observe the changes in the electronic absorption spectra of the compounds as a function of added DNA. Hence, we carried out the interaction of our compounds (10 µM) with DNA (0-100 µM) and the spectral changes observed are shown in (Figure 2 ). It can be seen from the figure that as and when the concentration of DNA is increased, a hyperchromism with a blue shift of 4 nm was observed for the ligand. But, for the complex, a hypochromism with a red shift of 3 nm was observed which indicates the existence of an intercalative mode of binding [48] .
Generally, compounds binding to DNA through intercalation results in hyperchromism or hypochromism with or without a small red or blue shift, due to a strong stacking interaction between the planar aromatic chromophore of the compound and the base pairs of DNA [49, 50] .
Further, to get an idea on the binding strength of the compounds, the intrinsic binding constants (Kb) of them with CT-DNA have to be determined from the following equation.
[
where, [DNA] is the concentration of DNA in base pairs, εa is the extinction coefficient of the complex at a given DNA concentration, εf is the extinction coefficient of the complex in free solution and εb is the extinction coefficient of the complex when fully bound to DNA. Table 2 which indicate that the complex interacts with BSA more strongly than the free ligand, a result which is similar to the one obtained from the CT-DNA absorbance titration [51] . In these types of studies, it is also important to determine the mechanism of quenching since there are two type of quenching namely, dynamic and static. Fluorophore-quencher complex formation in the ground state refers to static quenching while such a formation in the excited state corresponds to dynamic quenching. UV-Vis absorption spectroscopy can be employed determine the type of quenching and hence, we measured the UV-Vis spectra of BSA in the absence and presence of the test compounds and the spectra recorded are shown in (Figure 7 ).
The addition of the Cu complex to a fixed concentration of BSA led to a gradual increase in the intensity of BSA absorption at the same wavelength due to the interaction between the complex and protein, which is ascribed to the static quenching [52] . 
Synchronous fluorescence spectra
Tyrosine, tryptophan and phenylalanine residues are responsible for the fluorescence properties of BSA and one can find out the presence of any of these residues by measuring the synchronous fluorescence spectra of BSA with the compounds under study [53] . Hence, we measured the 
Cytotoxicity
The positive results obtained from the DNA and protein binding studies prompted us further to explore their in vitro cytotoxicity on cancer cell lines and we carried out the studies against A549
(lung cancer) and MCF7 (breast cancer) cell lines. The cell death inducing ability of the compounds was monitored by using the AO/EB staining assay and DAPI fluorescence study.
The inhibition at 24 h of cancer cell growth at 50 % level and IC50 values of the ligand and the complex are shown in (Table 3 ) and ( Figure 9 ). It is important to mention that the copper(II) complex presented herein showed better growth inhibitory effect than the previously reported copper complexes [57] [58] [59] [60] . The cytotoxic properties of this new Cu(II) complex can be attributed to the extended planar structure induced by the chelation of the quinoline ligand to the copper ion in the complex. The ligand also exhibited a moderate cytotoxic effect on A549 and MCF7 cancer cell lines compared to doxorubicin and cisplatin, with the copper(II) complex showed better activity against MCF7 cell line. 
Acridine orange /Ethidium bromide (AO/EtBr) staining Method
To establish the potential of any compound for a therapeutic use, it is essential to look at the 
DAPI staining method
Since it is necessary to confirm the nuclear condensation and fragmentation of the test 
Conclusion
A new Cu(II) complex synthesized has been fully characterized by using analytical and various spectral studies including the structure by X-ray crystallographic techniques. The ligand coordinated to the metal ion in a monobasic bidentate fashion. Binding study of both the ligand and complex with CT-DNA has been carried out which showed that they interact through intercalation mode. From the UV-visible and fluorescence spectroscopic studies, the binding interactions of the compounds with CT-DNA and bovine serum albumin protein were evaluated.
Furthermore, the compounds were tested against A549 (lung cancer) and MCF7 (breast cancer) cell lines and the results indicated significant cytotoxicity as evidenced by the IC50 values compared to the doxorubicin and cisplatin. The morphological changes examined by staining method suggested that the cell death mechanism was through apoptosis. The higher binding affinity and cytotoxic activity of the Cu(II) complex may be due to the extension of the π system of the intercalated ligand.
EXPERIMENTAL SECTION
Materials and methods
All the chemicals were purchased from sigma-Aldrich and were used as received. In the case of solvents, standard procedures were followed to purify them [61] . The metal complex, [CuCl2(PPh3)2] and ligand were prepared following the procedures reported in the literature Jasco FT-IR spectrophotometer. The melting points were recorded with a Lab India melting point apparatus. Elemental analyses were performed on a Vario EL III Elementaranalyser instrument. The electronic spectra of the compounds were recorded using a Jasco V-630 spectrophotometer. Emission spectra were measured using a Jasco FP 6600 spectrofluorometer.
1 H and 13 C NMR spectra were recorded on a Bruker AMX 500 NMR spectrometer. The X-band EPR spectrum of the complex was recorded at room temperature. DNA binding, protein binding [33, 34] and cytotoxicity [64] experiments were performed using the reported procedures. Transfer). EPR (X-band) at room temperature showed a spectrum with a 'g' value of 2.01.
Synthesis of ligand
Crystallography
X-ray diffraction experiments oof the complex was carried out at 100(2) K on a Bruker APEX II diffractometer using Mo-Kα radiation (λ = 0.71073 Å). Data collections were performed using a CCD area detector. Intensities were integrated in SAINT [65] and absorption corrections were carried out based on equivalent reflections using SADABS [66] . The structure was solved using Superflip [67, 68] and refined against F 2 in SHELXL [69, 70] using Olex2 [71] . All of the nonhydrogen atoms were refined anisotropically while all of the hydrogen atoms were located geometrically and refined using a riding model. 
